---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082719"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-07-10T21:13:07+00:00"
generated_at: "2026-07-10T21:14:07.744631+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M

## Summary
- Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.
- Shareholders approved 2,000,000 share increase under 2021 Stock Incentive Plan.
- Shareholders approved exercise of warrants for up to 39,618,078 shares of common stock.
- Deloitte & Touche ratified as independent auditor for fiscal year 2026.

## SEC filing metadata
- accession: 0001104659-26-082719
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-07-10T21:13:07+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/0001104659-26-082719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/tm2620219d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082719
- JSON: https://secwatch.observer/filing/0001104659-26-082719.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.